Match!
Daniel H. Lowenstein
University of California, San Francisco
Status epilepticusEpilepsyAnesthesiaMedicineBiology
179Publications
70H-index
17.5kCitations
What is this?
Publications 183
Newest
#1Gemma L. Carvill (NU: Northwestern University)H-Index: 21
#2Chris G. Dulla (Tufts University)H-Index: 11
Last. Amy R. Brooks-Kayal (University of Colorado Denver)H-Index: 37
view all 4 authors...
Abstract The epilepsies are a complex group of disorders that can be caused by a myriad of genetic and acquired factors. As such, identifying interventions that will prevent development of epilepsy, as well as cure the disorder once established, will require a multifaceted approach. Here we discuss the progress in scientific discovery propelling us towards this goal, including identification of genetic risk factors and big data approaches that integrate clinical and molecular ‘omics’ datasets to...
Source
#2Jaideep Kapur (UVA: University of Virginia)H-Index: 36
Last. Daniel H. Lowenstein (UCSF: University of California, San Francisco)H-Index: 70
view all 235 authors...
Summary Background Benzodiazepine-refractory, or established, status epilepticus is thought to be of similar pathophysiology in children and adults, but differences in underlying aetiology and pharmacodynamics might differentially affect response to therapy. In the Established Status Epilepticus Treatment Trial (ESETT) we compared the efficacy and safety of levetiracetam, fosphenytoin, and valproate in established status epilepticus, and here we describe our results after extending enrolment in ...
1 CitationsSource
#1Cora H. Ormseth (UCSF: University of California, San Francisco)
#1C. Ormseth (UCSF: University of California, San Francisco)
Last. Renee Y. Hsia (UCSF: University of California, San Francisco)H-Index: 33
view all 6 authors...
Source
#2Bassel Abou-KhalilH-Index: 41
#3Zaid AfawiH-Index: 22
Last. Melodie R. WinawerH-Index: 20
view all 67 authors...
Source
#1Hannah R. Cock (St George’s University Hospitals NHS Foundation Trust)H-Index: 17
#2Lisa D. Coles (UMN: University of Minnesota)H-Index: 10
Last. Jaideep Kapur (UVA: University of Virginia)H-Index: 36
view all 12 authors...
Abstract Convulsive status epilepticus (SE) is a relatively common emergency condition affecting individuals of all ages. The primary goal of treatment is prompt termination of seizures. Where first-line treatment with benzodiazepine has failed to achieve this, a condition known as established SE (ESE), there is uncertainty about which agent to use next. The Established Status Epilepticus Treatment Trial (ESETT) is a 3-arm (valproate (VPA), fosphenytoin (FOS), levetiracetam (LEV)), phase III, do...
Source
Source
#1Abhishek G. Sathe (UMN: University of Minnesota)H-Index: 1
#2Holly Tillman (MUSC: Medical University of South Carolina)H-Index: 7
Last. James C. Cloyd (UMN: University of Minnesota)H-Index: 16
view all 14 authors...
Benzodiazepines, including diazepam (DZP), lorazepam (LZP), and midazolam (MDZ), are considered the initial drugs of choice for status epilepticus (SE) treatment. A number of trials have demonstrated their safety and efficacy; however, the failure rate ranges from 10‐55%.1,2 This may be attributable, in part, to sub‐optimal benzodiazepine dosing and timing of administration. The Neurocritical Care Society (NCS) and American Epilepsy Society (AES) have published evidence‐based guidelines for benz...
1 CitationsSource
Sequencing-based studies have identified novel risk genes associated with severe epilepsies and revealed an excess of rare deleterious variation in less-severe forms of epilepsy. To identify the shared and distinct ultra-rare genetic risk factors for different types of epilepsies, we performed a whole-exome sequencing (WES) analysis of 9,170 epilepsy-affected individuals and 8,436 controls of European ancestry. We focused on three phenotypic groups: severe developmental and epileptic encephalopa...
9 CitationsSource
#2Roger P. SimonH-Index: 54
Source
Source
12345678910